This page shows the latest respiratory syncytial virus news and features for those working in and with pharma, biotech and healthcare.
It is estimated that infections caused by this respiratory virus lead to over 175, 000 hospitalisations and 14, 0000 deaths in older people in the US each year. ... disease (LRTD) caused by respiratory syncytial virus (RSV) in adults ages 60 and over.
Among these drugs, Enanta has produced therapies to address respiratory syncytial virus (RSV), human metapneumovirus (hMPV) chronic hepatitis B virus (HBV) and focused R&D efforts for COVID-19 early into
UK. Throughout the COVID-19 pandemic, Moderna worked with governments, healthcare professionals and other key stakeholders to help combat the virus and future pathogens. ... The company, with the support of the UK government, plans to use the site to
A private biopharma company, ReViral focuses on the discovery, development and commercialisation of antiviral therapeutics that are designed to target respiratory syncytial virus (RSV). ... RSV. ReViral has a portfolio of promising therapeutic candidates,
Pfizer has announced that the US Food and Drug Administration (FDA) has granted its respiratory syncytial virus (RSV) vaccine candidate a Breakthrough Therapy Designation. ... RSV is a contagious virus and is a common cause of respiratory illness, with
Sobi. This came about through a 2018 deal that saw Sobi gain the rights to sell AZ’s respiratory drug Synagis in the US. ... Synagis prevents serious lower respiratory tract infections caused by the respiratory syncytial virus in infants and young
More from news
Approximately 6 fully matching, plus 45 partially matching documents found.
Up to that point, the drug was being developed to treat respiratory viral infections in patients with COPD who are at risk of experiencing exacerbations, which can be deadly and typically ... challenge study, in this case respiratory syncytial virus (RSV)
In the absence of a knockout antiviral, researchers are trying to mitigate harmful effects of the virus. ... Scientists have since industrialised the concept, leading to the development of antibodies against Ebola and respiratory syncytial virus.
has encouraged people to knit hats and blankets for babies to alert people to respiratory syncytial virus.
In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD) ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur.
Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial virus (RSV) candidate SynGEM into pre-clinical studies.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...